17. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving TAB001;
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study therapy.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study treatment
Receipt of live attenuated vaccination within 30 days prior to the first dose of Vicinium or durvalumab
Receipt of live attenuated vaccination within 30 days prior to first anticipated dose of nivolumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab.
Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab, or active infection
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab OR tremelimumab.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry (or due to receive one within 30 days of receiving either MEDI4736 or tremelimumab)
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 6 months of receiving MEDI4736 or MEDI + tremelimumab
Receipt of live attenuated vaccination within 30 days prior to registration; NOTE: patients should also not receive such vaccination within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to receiving MEDI4736
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days after receiving the last dose of durvalumab.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days prior to study entry
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Receipt of live attenuated vaccination within 30 days prior to step 1 registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to first dose of MEDI4736
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Patients are ineligible if administration of a live, attenuated vaccine within 4 weeks before randomization
Administration of live vaccine within 4 weeks prior to study entry
Treatment with a live, attenuated vaccine within 4 weeks before initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such vaccine will be required during the study. Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo.
Administration of a live attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Patients should not receive immunization with attenuated live vaccine within one week of study entry or during study period
Treatment with therapeutic oral or intravenous (IV) antibiotics; or with a live, attenuated vaccine; or systemic immunosuppressive medication
Administration of a live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 or at any time during the study and for at least 5 months after the last dose of study drug
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Patients should not receive immunization with attenuated live vaccine within one week of study entry or during study period
Immunization with any attenuated live vaccine within 1 week prior to initiating protocol-indicated treatment.
Administration of a live vaccine within 4 weeks prior to study entry
Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that a live, attenuated vaccine will be required during atezolizumab/placebo treatment or within 5 months after the last dose of atezolizumab/placebo
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live vaccine within 6 weeks of first dose of study drug
Administration of a live vaccine within 4 weeks prior to start of protocol therapy
Administration of a live, attenuated vaccine within 4 weeks for first study treatment
Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy
Has received a live attenuated vaccine within 30 days prior to enrolling in the study.
Administration of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live vaccine within 6 weeks of first dose of study drug
Administration of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such vaccine will be required during the study\r\n* Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo
Live, attenuated vaccine within 30 days prior to day 1 of protocol therapy
Administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Patients who receive a live attenuated vaccine =< 28 days prior to registration are not eligible
Administration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study
Immunization with a live/attenuated vaccine within 30 days of enrollment
Administration of a live, attenuated vaccine within 4 weeks before first dosing or during the study.
Has received live, attenuated vaccine within 30 days prior to Study Day 1
Patient who requires live vaccine administration
Subject has received a live, attenuated vaccine within 28 days prior to Cycle 1 Day 1;
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Has received live, attenuated vaccine within 30 days prior to Study Day 1
Treatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMistÂ®) within 4 weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within 5 months after the final dose of study drug
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study, or up to 5 months following the anticipated last dose of atezolizumab
Administration of a live, attenuated vaccine within 4 weeks prior to enrollment
Live attenuated vaccine within 4 weeks of study drug
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Administration of attenuated vaccine within 4 weeks before enrollment
Administration of a live, attenuated vaccine within 4 weeks prior to randomization
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 Exclusion Criteria Unique to Cobimetinib:
Immunization with any attenuated live vaccine within 1 week prior to registration
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live/attenuated vaccine within 4 weeks prior to the first dose of study treatment, within 5 months following the administration of the last dose of study drug, or anticipation that such a live/attenuated vaccine will be required during the study
Administration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the study
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Administration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the study
Any plan to receive a live attenuated vaccine during study treatment
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Immunization with a live/attenuated vaccine within 28 days prior to conditioning
Administration of a live, attenuated vaccine within 4 weeks for first study treatment
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Immunization with a live, attenuated vaccine within 4 weeks prior to study enrollment
Live attenuated vaccine within 4 weeks prior to first day of study treatment
Receipt of a live, attenuated vaccine within 4 weeks prior to initiation of study drug (cycle 1, day 1 [C1D1]) or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within 28 days before Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Vaccination within 4 weeks of the first dose of avelumab and while on study is prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines).
Vaccination within 4 weeks of the first dose of avelumab and while on study.
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Vaccination within 28 days of the first dose of study drugs and while on trial is prohibited, except for administration of inactivated vaccines (for example, inactivated influenza vaccine).
Vaccine administration within 4 weeks of M7824 administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines).
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccine administration within 4 weeks of M7824 administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines).
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination (live attenuated virus) within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Live virus vaccination within 4 weeks of the first dose of avelumab (inactivated vaccines are allowed)
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Non-oncology vaccine therapies for prevention of infection disease (e.g. seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration; vaccination while on study is also prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines)
Any vaccination within 4 weeks of the first dose of avelumab, with the following exceptions:\r\n* Administration of inactivated vaccines, including inactivated flu vaccines, are allowable; however, they should not be given within 2 weeks prior to starting study treatment
Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within 28 days of the first dose of avelumab and while on trial is prohibited, except for administration of inactivated vaccines (for example, inactivated influenza vaccine)
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination with live inactivated viral strains for the prevention of infectious diseases within 4 weeks of the start of the study treatment, inactivated influenza vaccines are permitted while on trial
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines)
Vaccination within 4 weeks of the 1st dose of pembrolizumab and while on study is prohibited EXCEPT for administration of inactivated vaccines (e.g. inactivated influenza vaccine)
Vaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines;
Vaccination with live or live/attenuated viruses within 55 days of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines).
Vaccination within 4 weeks prior to the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within 4 weeks of study enrollment and while on trial is prohibited except for administration of inactivated vaccines.
Vaccination within 4 weeks of first dose of AGEN2034 and while on study except for administration of inactivated vaccines (e.g., inactivated influenza vaccines).
Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Patient who has received vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
At least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.
Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollment
Must not have received immunotherapy, eg, tumor vaccines, within 42 days.
At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines.
Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
Subjects must have completed any type of active immunotherapy (e.g., tumor vaccines) at least 42 days before study treatment initiation.
At least 42 days must have elapsed after the completion of any type of immunotherapy, e.g. tumor vaccines
Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines. Renal and Hepatic Function
At least 4 weeks since the completion of any type of immunotherapy, e.g. tumor vaccines
Receipt of live, attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Receipt of a live vaccine within 30 days prior to registration for protocol therapy
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo
Receipt of live vaccine within 28 days of planned first dose of TVEC
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of a live vaccine within 30 days of start of study treatment
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.
Receipt of a live vaccine =< 30 days prior to registration
Receipt of live attenuated vaccine within 30 days before the first dose of study treatment
Receipt of live attenuated vaccination within 30 days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP
Receipt of live attenuated vaccine within 28 calendar days prior to the first study treatment is NOT permitted
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)
Receipt of live attenuated vaccine within 30 days prior to study entry; enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumab
Receipt of a live vaccine within 30 days of receipt of study therapy
Receipt of a live virus vaccine =< 2 months prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of investigational products)
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for 180 days after the last dose of both drugs)
Receipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.
Receipt of a live vaccine within 30 days of study entry
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for 180 days after the last dose of durvalumab)
Receipt of a live, attenuated vaccine within 28 days prior to the first dose of MEDI4736 and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for 180 days after the last dose of both drugs)
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
Receipt of live vaccine within 30 days prior to the first dose of trial treatment
Receipt of any live vaccine within 4 weeks.
Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to 90 days after the last dose of study drugs
Receipt of live, attenuated vaccine within 30 days prior to study entry or the first dose of MEDI0457.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of durvalumab
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational product
Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for 30 days after the last dose of durvalumab).
Receipt of a live vaccine within 30 days before the first dose of study treatment.
Receipt of a live vaccine within 4 weeks prior to rituximab administration
Receipt of a live attenuated vaccine within 4 weeks prior to study drug
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product;
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
Receipt of a live vaccine within 30 days of receipt of study therapy
Receipt of a live (attenuated) vaccine within 1 month prior to Screening
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Receipt of a live vaccine within 30 days of receipt of study therapy
No receipt of a live vaccine within 4 weeks prior to registration
Chemotherapy or any other investigational agents within 14 days of first receipt of study treatment, or major surgery within 28 days of first receipt of study treatment, or palliative radiation within 7 days of first receipt of study treatment
Receipt of live vaccine within 4 weeks prior to study drug administration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be given
Receipt of any live vaccine within 4 weeks prior to first dose of study treatment.
Receipt of live attenuated vaccination within 30 days prior to the first vaccine
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and durvalumab treatment; subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugs
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of avelumab
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccine within 4 weeks or as recommended by the product manufacturer prior to the first dose, during treatment, or within 100 days of the last dose of JNJ-64407564
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting pembrolizumab treatment
Vaccinated with live, attenuated vaccine(s) within 28 days prior to first dose of study drug
Vaccinated with live, attenuated vaccine within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Patients should not be vaccinated with live attenuated vaccines within 30 days of starting durvalumab or tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of randomization
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patient has been vaccinated with live attenuated vaccines within 4 weeks before study vaccination
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Vaccinated with any of the vaccines planned for administration in the trial within 8 weeks of starting treatment on the study
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and/or durvalumab (MEDI4736) treatment
Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug
Vaccinated with live attenuated vaccines =< 4 weeks from starting study drugs
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
Subjects that have been vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug are not eligible
Patient must not be vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within 4 weeks of enrollment
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
Vaccinated with live, attenuated vaccines with 4 weeks of first does of study drug
Vaccinated with live, attenuated vaccines =< 4 weeks prior to registration
Vaccinated with live, attenuated vaccines within 4 weeks of treatment
Vaccinated with live, attenuated vaccines within 4 weeks of starting ibrutinib
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within four weeks of the first dose of study drug
Patients must not have received a live attenuated vaccination within 28 days prior to sub-study registration
Live vaccination is not allowed for at least 4 weeks prior to the start of AMG 757 treatment, during treatment, and until end of last study dose
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Has received a live vaccine within 30 days prior to the first dose of study drug; seasonal influenza vaccination is permitted excluding the nasal spray formulation
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Vaccination with a live vaccine < 28 days prior to the start of treatment
Received live or attenuated vaccination within 28 days prior to the start of NMA-LD
Live vaccination within the last 30 days
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Have received any live vaccination within 28 days of first dose of study drug
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Vaccination with live vaccines within 28 days prior to the start of Cycle 1
Vaccination with a live vaccine within 28 days of the initiation of treatment
Live attenuated vaccination administered within 30 days prior to randomization.
Vaccination with live vaccines within 28 days prior to start of treatment
have received any recent (within 28 days prior to randomization) live virus vaccination
Vaccination within 2 weeks of enrollment (except for annual flu vaccine).
Patients must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment
Patients must not have received a live attenuated vaccination within 28 days prior to sub-study registration
Patients must not have received a live attenuated vaccination within 28 days prior to RE-TREATMENT registration
Vaccination with a live vaccine within 28 days prior to treatment
Vaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Participants in Phase 1b Stage Only: Vaccination with live vaccines within 6 months before Cycle 1, Day 1
Vaccination with live vaccines within 28 days prior to randomization
Live-virus vaccination within 30 days prior to day 1 of protocol therapy
Vaccination with a live virus vaccine or live attenuated vaccine within 28 days prior to D1C1
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Vaccination with a live vaccine < 28 days prior to the start of treatment
Vaccination with a live vaccine a minimum of 30 days prior to study treatment
Vaccination with a live vaccine within 28 days of the initiation of treatment
Vaccination with a live vaccine within 28 days prior to randomization
Subjects who have received live virus vaccination within the 4 weeks prior to planned initiation of study treatment
Vaccination with a live vaccine within 28 days prior to randomization
Live vaccination within 4 weeks of the first dose of avelumab
Vaccination with a live vaccine a minimum of 28 days prior to randomization
Meningococcal vaccine(s) prior to LFG316 treatment if prior vaccination cannot be confirmed. The choice of vaccine(s) should take into account the serotypes prevalent in the geographic areas in which study patients will be enrolled. In case vaccination is not possible or will result in an unfavorable risk benefit ratio as judged by the investigator, vaccination can be postponed until deemed likely to be effective.
Patients <18 years old should receive vaccination for the prevention of S. pneumoniae and H. influenzae type b prior to LFG316 administration. In case vaccination is not possible or will result in an unfavorable risk benefit ratio as judged by the investigator, vaccination can be postponed until deemed likely to be effective.
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Vaccination with a live-virus vaccine up to 4 weeks prior to onset of study treatment.
Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment
Patients must not previously have received the Prevnar 13 pneumococcal vaccination; NOTE: previous vaccination with Pneumovax (PCV23) is permitted but must have been at least 365 days prior to registration
Vaccination with live vaccines within 28 days prior to treatment
Vaccination with a live vaccine a minimum of 28 days prior to the start of Cycle 1
Vaccination with live attenuated vaccine within 28 days prior to day 1 of PROSTVAC-V/F administration or vaccination with a killed vaccine within 14 days prior to day 1 of PROSTVAC-V/F
Have received a live vaccination within 30 days of study start.
Patients receiving live/attenuated vaccinations within 4 weeks prior to registration are not eligible
Use of any live vaccines within 4 weeks of initiation of study treatment
Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.
Use of live vaccines within four weeks of starting abatacept
Live vaccines within 30 days prior to the first dose of trial therapy and during trial treatment.
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
Administration of live vaccines within 21 days prior to enrollment
Received live attenuated vaccines within 30 days of first dose.
Any vaccinations four weeks prior to the first vaccination cycle or live vaccines at any time during the study
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Vaccine administration of live vaccines within 28 days of enrollment
Live attenuated vaccinations 14 days prior to treatment
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Current or recent treatment with therapeutic antibiotics, live attenuated vaccines or systemic immunostimulatory/immunosuppresive medication
Non-oncology vaccines within 28 days prior to or after any dose of ipilimumab
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment
Any live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumab
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Use of non-oncology vaccines containing live virus for prevention of infectious diseases within 12 weeks prior to study drug
Live vaccines within 28 days prior to study pre-registration
Patients should not receive immunization with attenuated live vaccines within one week (7 days) of study entry or during study period
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Live vaccines are not permitted within 28 days of study registration
Live attenuated vaccinations within 14 days prior to treatment
Live attenuated vaccinations 14 days prior to treatment
Patients receiving live vaccines due to the expected bone marrow toxicity (applicable to combination part only).
Use of live vaccines against infectious disease (e.g. varicella) within 28 days of initiation of study therapy; killed vaccinations (e.g. influenza) are allowed at any appropriate time before and during the study
Newly diagnosed MCL: Major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug
Treatment with a live virus vaccine during the 3 months prior to baseline visit; no live vaccines will be allowed throughout the course of this study
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment. Non-live vaccination (eg, influenza) are permitted anytime during treatment
Patients should not receive immunization with attenuated live vaccines =< 7 days of study entry or during study period
No immunizations with attenuated live vaccines within one week of study entry or during study period
Live-virus vaccines =< 28 days prior to registration
Previous treatment with radiotherapy, or immunotherapeutic agents, or receipt of live vaccines in the 4 weeks prior to study drug administration;
Use of any live vaccines within 4 weeks of initiation of study treatment.
Administration of live attenuated vaccines within 4 weeks of study enrollment.
Vaccination with live attenuated vaccines within 4 weeks of first study agent administration
TREATMENT: Patients who have received live attenuated vaccines within 1 week of the start are ineligible to receive everolimus
Patients who have received a live, attenuated vaccines within 4 weeks of first dose of drug
Patients should not receive immunization with attenuated live vaccines during study period or within 1 week of study entry
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Vaccination with live, attenuated vaccines within 4 weeks of first dose of study drug
received live vaccines.
Administration of live attenuated vaccines within eight weeks of start of study treatment (day -1) and throughout the study
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Patients taking live vaccines including yellow fever vaccinations
Administration of live vaccines =< 14 days prior to registration; note: patients may not receive any viral immunizations during the study and for 28 days after the last dose of Reolysin
Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study
Use of live or live attenuated vaccines within 30 days prior to randomization
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Patients who received live vaccines or who have close contact with people who have received live vaccines within 7 days of day 1 of study treatment
Unwilling to avoid vaccinations with live vaccine and concomitant use of attenuated live vaccines
Receipt of live vaccines against infectious diseases within 28 days;
Live or attenuated vaccines (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551
Receipt of live vaccines with 4 weeks (28 days) of study
Live attenuated vaccinations 14 days prior to treatment
Patients should not receive immunization with attenuated live vaccines during study period
Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization
Receive immunization with attenuated live vaccines within one week of randomization or during the study period.
Vaccination with live, attenuated vaccines within 4 weeks of first dose of this study
Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
Patients who have received vaccination with live attenuated vaccines within 6 months prior to registration are not eligible
Live attenuated vaccines
Live attenuated vaccines
Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
RECIPIENT: Live attenuated vaccines
Live in the community
Live attenuated vaccines within 90 days prior to leukapheresis.
Vaccination with live attenuated vaccines within 4 weeks of study agent administration
Subjects must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent.
Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment
Recent receipt of live attenuated vaccines.
Received live vaccines within 30 days prior to enrollment
